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The SOD mimetic tempol restores vasodilation in afferent
arterioles of experimental diabetes
CHRISTINE G. SCHNACKENBERG and CHRISTOPHER S. WILCOX
Division of Nephrology and Hypertension, Georgetown University Medical Center, Washington, D.C., USA
The SOD mimetic tempol restores vasodilation in afferent onstrated extensively in both human and animals models
arterioles of experimental diabetes. of diabetes [1–13]. However, the mechanisms responsible
Background. Endothelium-dependent vasodilation is im- for the impaired EDV remain unclear. Previous studiespaired in large conduit vessels in diabetes mellitus. Oxygen
using large conduit vessels suggest that the endothelium-radicals contribute to the impaired endothelium-dependent va-
derived contracting factor superoxide (O22) contributessodilation. We tested the hypothesis that stimulated endothe-
lium-dependent vasodilation is reduced in renal afferent arteri- to the impaired EDV in human and experimental diabe-
oles in diabetes and is caused by an increase in vascular tes [1, 3–5, 7, 11].
superoxide (O22). The endothelium modulates vascular function by re-Methods. Renal afferent arterioles from normal and insulin-
leasing relaxant substances such as nitric oxide (NO)treated alloxan-diabetic rabbits were microdissected and mi-
and constrictor substances such as O22. NO is producedcroperfused in vitro for the study of luminal diameter responses
to acetylcholine (Ach; 10211 to 1026 mol/L). The blood glucose constitutively in conduit and resistance vessels and medi-
concentration of insulin-treated alloxan-diabetic rabbits was ates the vasodilatory response to several agonists, includ-
elevated fourfold compared with normal rabbits (319 6 23 vs.
ing acetylcholine (Ach). Ach-induced vasodilations are79 6 6 mg/dL, P , 0.001).
impaired in isolated renal arteries [3] and isolated per-Results. In norepinephrine (NE)-preconstricted afferent ar-
terioles of normal rabbits, Ach significantly (P , 0.001) in- fused kidneys [12, 13] of diabetic animals. However, stud-
creased luminal diameter by 165 6 44%. The nitric oxide syn- ies in experimental and human diabetes show normal
thase inhibitor Nv-nitro-l-arginine methyl ester (1024 mol/L) relaxation to endothelium-independent vasodilators such
blocked this Ach-induced vasodilation. In marked contrast, in
as NO donors [1, 7]. Gryglewski, Palmer, and MoncadaNE-preconstricted arterioles of diabetic rabbits, Ach signifi-
have shown that O22 rapidly degrades NO, thus reducingcantly (P , 0.01) decreased luminal diameter by 41 6 11%.
Pretreatment of diabetic afferent arterioles with the superoxide its bioavailability [14]. Specific markers of oxidative
dismutase (SOD) mimetic tempol (1023 mol/L) restored a vaso- stress such as 8-iso prostaglandin F2a are increased in
dilator response to Ach. In NE-preconstricted diabetic afferent diabetic humans [15] and in rats induced with insulin-
arterioles treated with tempol, Ach significantly (P , 0.001)
dependent diabetes mellitus for 28 days [6]. Similarly,increased luminal diameter by 25 6 6%.
in the rat model of diabetes mellitus, we found recentlyConclusions. Ach-induced afferent arteriolar vasodilation is
dependent on nitric oxide and is impaired in diabetes. O22 that there is increased immunocytochemical expression
contributes to the impaired Ach-induced vasodilation in renal of the p47phox component of nicotinamide adenine di-
afferent arterioles in diabetes. nucleotide phosphate (NADPH) oxidase in the distal
nephron and increased renal excretion of lipid peroxida-
tion products (abstract; Onozato et al, J Am Soc Nephrol
Vascular diseases, including hypertension, atherosclero- 11:649A, 2000). These studies suggest that oxygen radi-
sis, retinopathy, nephropathy, and impotence, are common cals may be involved in the impaired EDV. In fact, treat-
complications in diabetes mellitus. Reduced endothe- ment with superoxide dismutase (SOD), which metabo-
lium-dependent vasodilation (EDV) is a common char- lizes O22, improves the basal release of NO in the systemic
acteristic of the vascular dysfunction and has been dem- [16] and renal [17] vasculature and improves Ach-induced
EDV in the aorta [5] of diabetic animals. Whether O22
is responsible for the impaired stimulation of EDV inKey words: oxygen radicals, superoxide, kidney, nitric oxide, endothe-
lium renal afferent arterioles in diabetes remains unknown.
All previous studies investigating stimulated EDV inReceived for publication August 15, 2000
isolated vessels of diabetics have used large conduit ves-and in revised form October 27, 2000
Accepted for publication November 20, 2000 sels or mesenteric and cerebral arterioles [1–11]. How-
ever, the overriding importance of renal resistance ves-Ó 2001 by the International Society of Nephrology
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sels in the control of blood pressure and renal function cation (Nomarski optics; Olympus Corp., Melville, NY)
on a video monitor via a black and white camera (modelis well established [18]. Since the kidneys have a funda-
mental role in diabetes and its associated cardiovascular NC 70; Dage-MTI, Inc., Michigan City, IN, USA) attached
to the inverted microscope and recorded on VHS tape.disease, we tested the hypothesis that stimulation of
EDV is reduced in renal afferent arterioles in diabetic Rabbit microperfused afferent arterioles were gradually
warmed to 378C and allowed to equilibrate for 30 min-rabbits and is caused by an increase in vascular O22.
Renal afferent arterioles from normal and early diabetic utes. All drugs were added to the superfusate. We have
shown previously that extraluminal application of in-rabbits were microdissected and microperfused in vitro
to study the luminal diameter responses to Ach. creasing concentrations of vasoactive agents obviates the
confounding effect of myogenic adjustments that are
caused by interrupting the luminal perfusion to change
METHODS
the luminal concentration of a drug [19]. L-NAME was
Animal model added to both the superfusate and perfusate. Using stan-
dard vernier calipers (Mitutoyo Corp., Aurora, IL, USA),Male New Zealand white rabbits (1.8 to 2.1 kg) were
maintained on tap water and standard chow. All proto- measurements of luminal diameter were made 10 to 15
minutes after administering the drugs. The point on thecols were approved by the Institutional Animal Care
and Use Committee of Georgetown University Medical afferent arteriole that showed consistent constriction or
dilation during an experiment was selected for study.Center and were performed according to the Guide for
the Care and Use of Laboratory Animals of the National
Experimental designInstitutes of Health, as well as the guidelines of the Animal
Welfare Act. Rabbits were divided into two groups: nor- Series 1. The aim of this series was to determine the
afferent arteriolar luminal diameter response to Ach inmal and diabetic. Rabbits were made diabetic using a
single bolus injection of alloxan (100 mg/kg, IV) as pre- normal rabbits. Afferent arterioles were preconstricted
with norepinephrine (NE; 5 3 1028 mol/L) to increaseviously described [2]. Insulin (Humulin N, Eli Lilly, 1.0
to 2.0 U/day, sq) was administered, and blood glucose resting vascular tone. Then luminal diameter was mea-
sured during basal conditions and after increasing dosesconcentrations were monitored (Accu-Chek; Boehringer
Mannheim Corp., Mannheim, Germany) daily in dia- of Ach (10211 to 1026 mol/L) in NE-preconstricted affer-
ent arterioles of normal rabbits (N 5 6).betic rabbits. Ten days after the induction of diabetes,
rabbits were sacrificed for the study of afferent arteriolar Series 2. The objective of this series was to determine
the role of NO in the afferent arteriolar response tofunction.
increasing doses of Ach in normal rabbits. Afferent arte-
Isolation and microperfusion of afferent arterioles rioles were pretreated with the NO synthase inhibitor
Nv-nitro-l-arginine methyl ester (L-NAME; 1024 mol/L)Rabbits were anesthetized with xylazine (9 mg/kg,
IM), ketamine (47 mg/kg, IM), and sodium pentobarbitol at a dose that has previously been shown to block Ach (10
mmol/L)-induced vasodilation of normal rabbit afferent(11 mg/kg, IV) followed by heparin (1000 USP, IV) for
anticoagulation. Microdissection and microperfusion of arterioles [20]. Luminal diameter was measured during
basal conditions and after increasing doses of Ach (10211the afferent arteriole were performed as previously de-
scribed [19, 20]. Briefly, the right kidney was extracted to 1026 mol/L) in L-NAME–pretreated afferent arteri-
oles of normal rabbits (N 5 4).via an abdominal incision and immediately placed in ice-
cold preservation solution. Slices of the kidney were Series 3. The aim of this series was to determine the
afferent arteriolar luminal diameter response to Ach inmade along the corticomedullary axis and replaced in
the preservation solution. A single superficial afferent diabetic rabbits. Afferent arterioles were preconstricted
with NE (5 3 1028 mol/L) to increase resting vasculararteriole with glomerulus attached was microdissected
under a stereomicroscope (model SZ40; Olympus Corp., tone. Luminal diameter was measured during basal con-
ditions and after increasing doses of Ach (10211 to 1026Melville, NY) on a stage maintained at 48C. The arteriole
was transferred to a temperature-regulated chamber mol/L) in NE-preconstricted afferent arterioles of dia-
betic rabbits (N 5 6).mounted on the stage of an inverted microscope (model
IX70; Olympus Corp.) modified with micromanipulators. Series 4. The objective of this series was to assess the
role of O22 in the luminal diameter response to Ach inThe afferent arteriole was cannulated with a series of
concentric glass pipettes including holding, perfusion, diabetic rabbits. Afferent arterioles were preconstricted
with NE (5 3 1028 mol/L) to increase resting vascularand exchange pipettes and perfused at 60 mm Hg with
alpha modification of minimum essential media (MEMa). tone. Then afferent arterioles were pretreated with the
SOD mimetic tempol (1023 mol/L) at a dose that weThe arteriole was superfused at approximately 1 mL/
min with MEMa bubbled with 95% O2/5% CO2. The have previously shown blocks the luminal diameter re-
sponse to O22 generated in the afferent arteriole by amicroperfused arteriole was displayed at 3400 magnifi-
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Fig. 1. Series 1 and 2. The percentage change in luminal diameter from Fig. 2. Series 1 and 3. The percentage change in luminal diameter from
baseline (basal) during acetylcholine (Ach) in normal afferent arterioles baseline (basal) during acetylcholine (Ach) in afferent arterioles from
pretreated with either norepinephrine (NE; 5 3 1028 mol/L, N 5 6; d) normal (d; N 5 6) and diabetic (j; N 5 6) rabbits. Comparing the
or Nv-nitro-l-arginine methyl ester (L-NAME, 1024 mol/L, N 5 6; j). two groups: *P , 0.05; ***P , 0.001.
Comparing the two groups: *P , 0.05; **P , 0.01; ***P , 0.001.
quinolone [19]. Luminal diameter was measured during rioles were pretreated with either NE or L-NAME to
basal conditions and after increasing doses of Ach (10211 examine the role of NO in the vasodilator response to
to 1026 mol/L) in diabetic NE-preconstricted afferent Ach. NE significantly (P , 0.001) decreased resting lumi-
arterioles pretreated with tempol (N 5 6). nal diameter (16.63 6 1.42 mm) by 45 6 6% in afferent
arterioles of normal rabbits. Ach dose-dependently va-Drugs and solutions
sodilated (P , 0.001) NE-preconstricted afferent arteri-
All agents, including alloxan, NE, tempol (4-hydroxy oles. Ach maximally increased luminal diameter by 165 6
TEMPO), and L-NAME, were purchased from Sigma 44% from baseline (9.17 6 1.43 mm, P , 0.001). In
Chemical Co. (St. Louis, MO, USA) and prepared marked contrast, Ach dose-dependently vasoconstricted
fresh daily. Heparin was dissolved in 0.9% NaCl at
afferent arterioles pretreated with L-NAME. L-NAME1000 USP/mL. The preservation solution consisted of
pretreatment decreased resting luminal diameter (14.76 6150 mmol/L sucrose, 52 mmol/L NaHPO4 (anhydrous), 0.72 mm) by 28 6 9%, which was not significantly differ-16 mmol/L NaH2PO4, and 5% bovine serum albumin
ent from NE pretreatment. Ach administration after(BSA). It was filtered (0.8 mm), saturated with 95%
L-NAME maximally reduced luminal diameter by 56 6O2/5% CO2 (pH 7.40 to 7.45), and prepared fresh daily.
12% from baseline (10.42 6 0.85 mm). The overall lumi-MEMa solution containing standard concentrations of
nal diameter response to Ach of L-NAME–pretreatedglucose (100 mg/dL) and l-arginine (126.40 mg/L) and an
afferent arterioles was significantly (P , 0.05) less thanadditional 26 mmol/L NaHCO3 and 5% BSA for perfusion
NE-pretreated afferent arterioles.and 26 mmol/L NaHCO3 and 0.15% BSA for superfusion
were filtered (0.2 mm), saturated with 95% O2/5% CO2,
Series 3and buffered to pH 7.40 to 7.45 before use daily.
The blood glucose concentration of insulin-treated al-
Statistics loxan-diabetic rabbits was elevated fourfold compared
All values are reported as mean 6 SE. Overall signifi- with normal rabbits (319 6 23 vs. 79 6 6 mg/dL, P ,
cance within and between groups was determined using 0.001). Figure 2 shows the luminal diameter response
repeated-measures analysis of variance. Scheffe’s post to Ach of NE-preconstricted afferent arterioles from
hoc test was applied when significant differences between diabetic rabbits and is compared with the response from
groups were found using analysis of variance. A Student normal rabbits (Fig. 1). Whereas Ach significantly (P ,
t test was used to determine significant differences of
0.001) vasodilated NE-preconstricted afferent arteriolesindividual responses between groups. P , 0.05 was deter-
of normal rabbits, Ach significantly (P , 0.01) vasocons-mined to be significant.
tricted NE-preconstricted afferent arterioles of diabetic
rabbits. In diabetic rabbit afferent arterioles, NE signifi-
RESULTS cantly (P , 0.001) decreased resting luminal diameter
Series 1 and 2 (14.74 6 0.33 mm) by 26 6 3%. Ach maximally (P ,
0.001) reduced luminal diameter by 41 6 11% fromFigure 1 illustrates the afferent arteriolar luminal di-
ameter response to Ach in normal rabbits. Afferent arte- baseline (10.95 6 0.65 mm) in NE-preconstricted diabetic
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vessels after several weeks of diabetes. Some investiga-
tors suggest, however, that impaired Ach-induced EDV
in diabetic vessels is time dependent. Pieper found that
Ach-induced EDV in rat aorta is increased, unaltered,
or impaired after 24 hours, 1 or 2 weeks, or 8 weeks of
diabetes, respectively [8]. Similarly, Diederich et al re-
port that the Ach-induced EDV of rat aorta is increas-
ingly impaired after 6, 16, and 24 weeks of diabetes
[4]. Our data show that the renal afferent arteriole has
impaired stimulated EDV after 10 days of diabetes. We
suggest that impaired Ach-induced EDV in diabetes may
occur earlier in renal resistance arterioles than in larger
conduit arteries.
Fig. 3. Series 3 and 4. The percentage change in luminal diameter This study indicates that Ach stimulates the release
from baseline (basal) during acetylcholine (Ach) in NE-preconstricted of a contractile factor in afferent arterioles of diabeticafferent arterioles in the presence (j; N 5 6) or absence (d; N 5 6)
rabbits. The contractile response to Ach of diabetic arte-of tempol (1023 mol/L). Comparing the two groups: *P , 0.05; ***P ,
0.001. rioles is similar to that found in diabetic aorta [10]. One
widely held hypothesis is that Ach stimulates the release
of endothelium-derived contracting factors such as O22
in vessels with impaired EDV. In fact, renal and systemic
afferent arterioles. The overall luminal diameter re- vascular dysfunction in diabetes has been associated with
sponse to Ach of diabetic afferent arterioles was signifi- oxidative stress. The basal vascular response to NO syn-
cantly (P , 0.001) less than normal afferent arterioles. thesis inhibition in the renal microcirculation of diabetic
rats has been reported previously to be reduced com-Series 4
pared with normal rats and subsequently improved with
Figure 3 displays the role of O22 in the vasoconstrictor SOD [17]. Furthermore, the impaired stimulated EDV
response to Ach of NE-preconstricted afferent arterioles of mesenteric arteries [9] and aorta [5] of diabetic rat
of diabetic rabbits. NE-preconstricted afferent arterioles and forearm vessels of diabetic patients [11] is improved
were pretreated with tempol and compared with the data by scavenging oxygen radicals. The results of the present
shown in Figure 2 for diabetic rabbits. Whereas Ach studies extend those observations, revealing that the
significantly (P , 0.01) vasoconstricted NE-preconstricted stimulation of NO-dependent EDV is improved in dia-
diabetic afferent arterioles pretreated with vehicle, Ach betic afferent arterioles treated with the SOD mimetic
significantly (P , 0.001) vasodilated NE-preconstricted tempol. Tempol has no time-dependent effect [19] and
diabetic afferent arterioles pretreated with tempol. In no effect on basal vascular tone of afferent arterioles
diabetic rabbit afferent arterioles, NE decreased resting from normal [19] or diabetic rabbits, indicating that tem-
luminal diameter (17.25 6 1.97 mm) by 27 6 6%. Tempol pol does not have nonspecific effects on afferent arteriole
pretreatment had no effect on luminal diameter of NE- tone. Since scavenging of O22 with tempol before Ach
preconstricted diabetic afferent arterioles (NE, 12.53 6 treatment did not change baseline luminal diameter of
1.61 mm; NE 1 tempol, 12.98 6 1.59 mm, P 5 NS). Ach NE-precontracted diabetic afferent arterioles, the level
maximally (P , 0.001) increased luminal diameter by of superoxide present during basal conditions was mini-
25 6 6% in diabetic afferent arterioles pretreated with mal. However, since scavenging of superoxide during
tempol. The overall luminal diameter response to Ach Ach significantly altered the response to Ach of NE-
of diabetic afferent arterioles pretreated with tempol was precontracted diabetic afferent arterioles, the data sup-
significantly (P , 0.001) greater than diabetic afferent port the hypothesis that Ach stimulates the release of
arterioles pretreated with vehicle. O22 in diabetic vessels. In addition to the direct contrac-
tile effects of O22 on vascular smooth muscle [21], Gry-
glewski, Palmer, and Moncada report that O22 rapidlyDISCUSSION attacks and inactivates NO [14]. Therefore, we suggest
This study shows, to our knowledge for the first time, that metabolism of O22 by tempol improves Ach-induced
that Ach-induced EDV is impaired in afferent arterioles EDV in afferent arterioles likely by increasing the bio-
in diabetes. Our results are similar to other reports of availability of NO, but could also be due to decreasing
impaired Ach-induced EDV in large conduit vessels of the action of O22 on smooth muscle.
the renal [3] and systemic circulations [1, 2, 5–7, 9–11] Since scavenging of O22 did not normalize the re-
of diabetic humans and animals. These studies showed sponse to Ach of diabetic afferent arterioles, other con-
tractile factors or mechanisms must be involved in thethat stimulated Ach-induced EDV is impaired in large
Schnackenberg and Wilcox: Tempol in diabetic arterioles 1863
vascular dysfunction. Previous investigations have shown whether prostaglandins directly are altering the segmen-
tal renal vascular resistance. In fact, Edwards showedthat metabolism of H2O2 normalizes the Ach-induced
EDV of diabetic renal arteries [3]. Since endogenous that meclofenamate has no effect on Ach-induced vaso-
dilation of isolated, perfused rabbit afferent arterioleslevels of H2O2 are a result of the balance between its
generation from O22 by SOD and its degradation by [28]. Thus, the role of prostaglandins in the present study
was not investigated. Finally, all previous studies investi-catalase, it is probable that H2O2 levels are elevated in
the diabetic afferent arteriole and could contribute to gating stimulated EDV in the renal circulation of dia-
betic animals have used whole animal [29] or isolatedthe impaired EDV. In vitro studies have shown that
tempol enhances the catalase-like activity of the heme- perfused kidney techniques [12, 13]. Because NO is pres-
ent in several cell types including the endothelial, maculaprotein MbFeIII and prevents H2O2-induced cellular tox-
icity [22]. Therefore, tempol could improve EDV by densa, and epithelial cells that impact on the afferent
arteriole [30], the site of the impaired EDV in the previ-reducing the tissue levels of both O22 and H2O2. More-
over, it seems improbable that H2O2 levels after tempol ous studies remained uncertain. The present study shows
that the impaired Ach-induced EDV in diabetes is intrin-treatment were sufficient to impair EDV responses in
the diabetic rabbit afferent arterioles. Other studies have sic to the afferent arteriole.
Previous studies have shown that in vitro treatmentshown that blockade of TxA2/PGH2 (TP) receptors im-
proves the relaxant response to Ach in diabetic renal of normal aortic rings with 1.5 mmol alloxan had no
effect on Ach-induced EDV [8]. Therefore, the impairedarteries [3] and aorta [10]. We have reported previously
that the vasoconstriction during activation of TP-recep- responses of isolated, perfused afferent arterioles of allo-
xan-diabetic rabbits are not likely due to a direct effecttors with U-46,619 is inhibited strongly by tempol in
afferent arterioles of normal rabbits [19]. Thus, it is not of alloxan on the vessels. Tesfamariam et al showed that
increasing the glucose concentration of the bath fromclear whether the stimulation of TP receptors is impor-
tant in the remaining impaired Ach-induced EDV in 5.5 to 44 mmol/L increased the release of endothelial-
derived contracting factors from normal rabbit aortadiabetic renal afferent arterioles treated with tempol.
The use of the in vitro microperfused renal afferent [31]. Furthermore, studies by Arima et al suggest that
high glucose treatment of in vitro microperfused rabbitarteriole technique in these studies has several advan-
tages over other methodologies used to study EDV in afferent arterioles impairs NO synthesis [32]. In the pres-
ent study, the glucose concentrations of the perfusatethe kidney. First, since renal afferent arterioles are the
primary site of resistance in the renal circulation, their and superfusate were maintained normal (0.1 mmol/L)
for all studies, thus eliminating any direct acute effectsresponse to stimulated EDV in diabetes is of central
importance to kidney function. Second, afferent arterio- of hyperglycemia on afferent arteriolar function.
Hyperfiltration is a common characteristic of renallar tone is a result of a number of factors. Afferent
arterioles respond rapidly to changes in perfusion pres- hemodynamics during the early stage of diabetes [33].
What is the physiological relevance of an impaired stimu-sure (myogenic response) and to changes in NaCl deliv-
ery to the macula densa (tubuloglomerular feedback re- lated EDV in the afferent arteriole when overall renal
hemodynamic function is markedly elevated? Some stud-sponse). In the present study, perfusion pressure was
held constant, and the macula densa was not present in ies indicate that a reset of the tubuloglomerular feedback
response plays a dominant role in the hyperfiltration inorder to eliminate the myogenic and tubuloglomerular
feedback (TGF) responses. This is important since both the early stage of diabetes [34]. This could be secondary
to enhanced NO synthesis in the macula densa, whichmyogenic and TGF responses of afferent arterioles are
impaired in diabetes [23, 24] and are due, in part, to an contributes to the hyperfiltration in diabetes (abstract;
Komine et al, J Am Soc Nephrol 10:684A, 1999). As aalteration in NO action [25, 26]. Therefore, the in vitro
technique that we employed to manipulate NO produc- result, the underlying impairment of EDV in the afferent
arteriole may be masked by the enhanced production oftion with L-NAME should not have had confounding
effects mediated by TGF or myogenic responses. Affer- macula densa-derived NO and reduced tubuloglomeru-
lar feedback response in the early stage of diabetes.ent arterioles also respond to other factors such as pros-
taglandins, which are important in mediating the renal Therefore, study of isolated, perfused afferent arterioles
in the absence of tubuloglomerular feedback provideshemodynamic actions of Ach in the anesthetized rabbit
[27]. However, prostaglandins are thought to participate novel information regarding the integrative mechanism
of renal microvascular dysfunction in diabetes. It remainsin the regulation of renal hemodynamics by a variety of
mechanisms including vasodilation, attenuation of vaso- to be shown whether an impaired Ach-induced EDV of
the afferent arteriole is important for the developmentconstrictor stimuli, reduction of NE release, stimulation
of renin release, and modulation of the glomerular ultra- of renal dysfunction in the later stages of diabetes.
In conclusion, the normal NO-dependent vasodilatoryfiltration coefficient. Because of these diverse actions, it
is often difficult to determine in the intact kidney response to Ach of afferent arterioles is replaced by
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dent relaxation (nitric oxide) in diabetic kidneys. Horm Metab Resa vasoconstrictor response in arterioles from diabetic
30:55–57, 1998
rabbits. Superoxide plays a significant role in the contrac- 13. Kamata K, Hosokawa M: Endothelial dysfunction in the perfused
kidney from the streptozotocin-induced diabetic rat. Res Communtion. However, since the impaired EDV of diabetic affer-
Mol Pathol Pharmacol 96:57–69, 1997ent arterioles was not completely restored by an agent 14. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide anion is
that metabolizes O22, other factors are likely involved involved in the breakdown of endothelium-derived vascular re-
laxing factor. Nature 15:170–179, 1986in the vascular dysfunction.
15. Gopaul NK, Anggard EE, Mallet AI, et al: Plasma 8-epi-PGF2a
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